title: Do bisphosphonates and statins have a role in spondyloarthritis management?
abstract: Bisphosphonates and statins target the mevalonate pathway of biosynthesis of prenyl groups, which are necessary for the lipid modification of small GTP-binding proteins (eg, Ras, Rac, Rho) that transduce a wide array of extracellular growth and differentiation signals from cell surface receptors to the nucleus. Interference with this pathway has been shown to confer beneficial anti-inflammatory properties in vitro and in animal models of inflammation. Primarily open-label data in spondylo-arthritis suggests mild to moderate efficacy on symptoms and function but their primary clinical role may be as adjunctive therapy to manage systemic osteoporosis and risk for cardiovascular events.
authors.affiliation: University of Alberta, Edmonton, Alberta T6G 2S2, Canada. walter.maksymowych@ualberta.ca
authors.forename: Walter P
authors.initials: WP
authors.lastname: Maksymowych
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D025242:Spondylarthropathies / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors